dermatology

Closing gaps in HS care through community engagement and scientific innovation

Borysiuk Viktor (External) — Wed, 20 Nov 2024 10:25:57 +0000

Closing gaps in HS care through community engagement and scientific innovation

Rhonda Peebles, Dermatology US

Borysiuk Vikto… Wed 20/11/2024 - 11:25

This past summer, ��ֳ� welcomed members of the hidradenitis suppurativa (HS) community – dozens of people living with HS, caregivers, advocacy groups, and medical experts – onto our Atlanta campus for our HS Summit to advance understanding of the treatment journey and unmet needs of those impacted by this disease.

It was incredibly powerful to hear patient testimony firsthand throughout the weekend. I was struck by the openness and honesty of the community as they shared their physical and emotional struggles and the importance of speaking up. Engaging with the HS community and witnessing their strength and perseverance is one of the most rewarding and inspiring parts of my job at ��ֳ�.

Hearing insights and experiences from the HS community have encouraged our drive to bring a new treatment option to people living with this painful, chronic inflammatory skin condition. Today, I’m excited and proud that dermatologists have more options than ever to effectively manage HS.

Our efforts to support both patients and clinicians are ongoing and go far beyond treatment. One big initiative is supporting a registry of HS patients in partnership with the University of California San Francisco (UCSF), which will facilitate research of this disease through collaboration between investigators, clinicians, patients, and industry to improve the lives of people living with HS. We are also proud to sponsor the HS Papaya app, which was developed by two leading HS physicians to help people living with HS track their symptoms and communicate those to their provider, connect with an HS center of excellence, and more. And at the recent Symposium on Hidradenitis Suppurativa Advances (SHSA) conference, we shared new HS data and met with key third party medical and patient advocacy organizations to advance our collaborative initiatives. These are just a few of the things we’re doing as we aim to establish leadership in HS and dermatology.

As advocacy leader Brindley Brooks, co-founder and president of HS Connect, said at the HS Summit, “There’s never a good time to have HS, but there’s never been a better time to have HS.” I am inspired each day as I work alongside those with such a dedication to improving the lives of people impacted by HS. It is a hopeful time. As we forge forward, I know that there will continue to be more treatment options, awareness, and support resources for HS patients – and I am honored to be part of this new era for HS care.

about ucb

HS dermatology science

140 Likes

World Psoriasis Day 2024: Celebrating the invaluable role of family

Borysiuk Viktor (External) — Tue, 29 Oct 2024 13:07:51 +0000

World Psoriasis Day 2024: Celebrating the invaluable role of family

Snauwaert Adriaan, Immuno Global Communication

Borysiuk Vikto… Tue 29/10/2024 - 14:07

Today, Tuesday, 29th October, marks World Psoriasis Day. For more than a decade, the global community has come together on this day to raise awareness and unite in their support of people living with psoriasis and psoriatic arthritis.

Each year, the International Federation of Psoriasis Associations (IFPA) selects a theme for World Psoriasis Day. This year’s theme, ‘Psoriatic Disease and the Family’, aims to raise awareness of the impact living with psoriasis and psoriatic arthritis can have on both people living with these diseases and their family members.

To mark World Psoriasis Day and this year’s theme, we had the honor of an insightful conversation with Caroline, who lives with psoriasis and psoriatic arthritis.

Diagnosed with plaque psoriasis at age 9, Caroline initially received creams for symptom relief. At 19, she was also diagnosed with psoriatic arthritis. For over twenty years, Caroline struggled to manage both her psoriasis and psoriatic arthritis, which sometimes resulted in extended hospital stays. Caroline’s journey was transformed by the support and encouragement of her dermatologist. This dedication and care made a world of difference in her life. Additionally, by connecting with others who faced similar challenges and actively engaging with patient advocacy groups, Caroline discovered a wealth of knowledge and support. These connections and the community supported her to live well with psoriatic disease.

Our conversation with Caroline emphasized the important role family members can play in helping their loved ones thrive while living with psoriatic disease, offering valuable insights into the power of support and understanding.

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

Psoriasis affects everything. The constant itching, the bleeding, the ugliness of it. Psoriasis dictates everything, and I had to learn to cover it up quite cleverly. I couldn’t wear nice dresses and shorts and would avoid dark jackets.
For a while, I had a futile feeling that nothing could be done. It is only when I look back now that I realize how deeply psoriasis and psoriatic arthritis affected me – I can’t believe that it is only in the last couple of years that I have been able to wear shorts and short sleeves.

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

Family support is really important, particularly the practical support they provide. The itch with psoriasis is terrible, so buying or helping to apply creams and lotions that will tackle this is a really simple way family members can support someone living with psoriasis or psoriatic arthritis. It is also very easy for someone living with these conditions to get despondent with the thought that their psoriasis or psoriatic arthritis is never going to go away; encouragement from family members to see a dermatologist and keep pushing to get the right care can be hugely important in not giving up hope. Outside of the family, I have personally found that having a strong support network of people who have shared experiences of living with psoriasis or psoriatic arthritis has taught me so much – from simply picking up tips to being surrounded by people who know exactly what you are going through.

What support or resources do family members need to deepen their awareness and understanding of the conditions?

Education is empowerment – there is not much family members can do without first educating themselves with the facts. By reading information provided by support groups, family members can arm themselves with knowledge around what psoriasis or psoriatic arthritis is. Additionally, to help family members empathize with their loved ones, I think it is important they hear the realities of living with psoriasis and psoriatic arthritis through patient testimonials.

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

I often hear from people living with chronic psoriasis ‘what is the point of even trying anymore’ – they lose hope when their psoriasis keeps coming back. It gives you comfort to talk to people who know how you’re feeling or have similar experiences, it can be a lifeline. Getting the right doctor, the right diagnosis, the right treatment for you and the right information is so important. Don’t give up. Remember, your support and understanding can make a world of difference providing the strength and hope that family members need to live well with their condition and advocate for themselves.

This World Psoriasis Day, we celebrate the invaluable role of family. We extend our heartfelt gratitude to Caroline for sharing her perspective. Her insights into the potential practical and emotional support that can be provided by family and friends highlight the importance of a strong support network. Together, we aim to raise awareness and deepen understanding of psoriasis and psoriatic arthritis.

about ucb

World Psoriasis Day dermatology Immunology

123 Likes

��ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

Vandenbruaene Nathalie — Wed, 25 Sep 2024 07:06:18 +0000

��ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

Eimear O'Brien, Corporate Communications

Vandenbruaene … Wed 25/09/2024 - 09:06

As the European Academy of Dermatology and Venerology (EADV) annual congress approaches, ��ֳ� proudly reaffirms its commitment to advancing immuno-dermatology care. This prestigious event unites leading dermatologists, scientists, and healthcare professionals to share the latest research and address critical unmet needs. We are excited to explore how the scientific advancements showcased at this year’s congress in Amsterdam can enhance our ability to serve people living with dermatological diseases.

��ֳ� stands with the scientific, medical, and patient communities, working together to raise the standard of care in immuno-dermatology. Our participation at EADV reflects our commitment to investing in the science that can enable better outcomes for people living with immune-mediated inflammatory diseases. This year, we are proud to have 23 abstracts accepted across our immuno-dermatology portfolio contributing to the understanding of conditions like psoriasis, psoriatic arthritis (PsA) and hidradenitis suppurativa (HS).

Our exhibition booth this year will serve as an exciting hub for engagement and education. We will share our disease awareness initiatives in HS to deepen understanding of this painful and often debilitating condition. Visitors can also learn about our ongoing research, patient support programs, and our commitment to improving the lives of those affected by dermatological diseases.

As part of our commitment to furthering knowledge and understanding in dermatology, we are hosting two scientific symposia that will delve deeper into psoriasis and HS.

As we look forward to EADV 2024, ��ֳ� remains steadfast in our mission to advance immuno-dermatology care. By collaborating with the scientific and medical communities, and championing research, we are committed to improving patient outcomes.

If you are a healthcare professional attending EADV, join us at our scientific symposia or visit our booth to learn more. We look forward to meeting you in Amsterdam!

about ucb

EADV European Academy of Dermatology and Venereology dermatology Immuno-Dermatology

173 Likes

Advocating for Change in the Lives of People with Hidradenitis Suppurativa

Vandenbruaene Nathalie — Fri, 12 Apr 2024 08:00:37 +0000

Advocating for Change in the Lives of People with Hidradenitis Suppurativa

Danuta Marchi, External Engagement, Immuno-Dermatology and Rheumatology

Vandenbruaene … Fri 12/04/2024 - 10:00

At ��ֳ�, we are committed to improving the lives of people living with hidradenitis suppurativa (HS), a chronic, painful, inflammatory skin condition that can have a significant and detrimental impact on patients’ lives.

Today, there are several barriers for people living with HS, which can impede their ability to live life to the fullest potential. These include insufficient awareness of HS and delays in diagnosis. These factors can impact the timely and appropriate care that people with HS receive. Additionally, the stigma associated with the disease can negatively affect mental wellbeing and interpersonal relationships.1 Addressing these barriers is a crucial step towards improving lives.

A new international report, Call to action: improving the lives of people with hidradenitis suppurativa (HS), published by The Health Policy Partnership (HPP), communicates the condition’s significant impact and advocates for change by highlighting policy and system barriers to better HS care. The report, published in February 2024, was led by HPP with guidance from a multi-disciplinary Steering Committee. It was developed based on literature review as well as some interviews with people living with HS and healthcare professionals. The research focused largely on ten countries - Canada, Denmark, France, Germany, Italy, Japan, the Netherlands, Spain, Sweden and the United Kingdom. The insights from people living with HS contained in the report serves as a powerful call to action for a deeper understanding of the impact of this debilitating disease on patients’ lives.

The report highlights ten priority recommendations including raising awareness of HS among the general public, employers and healthcare professionals. The focus on increased awareness with these audiences aims to mitigate stigma, encourage people to seek care, accommodate the needs of employees living with HS and improve referral rates and the speed of diagnosis. You can read the full list of recommendations in the online report here.

At ��ֳ�, we firmly believe that implementing these recommendations will significantly enhance the lives of people with HS. By collaborating with the community to enact these changes, we can collectively help to ensure that people living with HS receive the necessary care and support they need today and into the future.

This report was developed as part of a project which is led by The Health Policy Partnership with guidance from a multidisciplinary Steering Committee. HPP was commissioned by ��ֳ�, which initiated and funded the project.

solutions

Hidradenitis Suppurativa HS dermatology Immunology

Comment:

Posted by Takieyah Mathis, 17 April 2024

Thank you for bringing a spotlight to this condition!

394 Likes

��ֳ� Looks Forward to Joining the HS Community at #EHSF2024

Andrea_Puletto — Wed, 07 Feb 2024 11:19:48 +0000

��ֳ� Looks Forward to Joining the HS Community at #EHSF2024

Eimear O'Brien, Global Communications and Company Reputation

Andrea_Puletto Wed 07/02/2024 - 12:19

The 13th Conference of the European Hidradenitis Suppurativa Foundation is taking place this week in Lyon, France (Feb 7-9). At ��ֳ�, we have a longstanding commitment to developing and delivering science that will make a difference in the lives of people with immuno-dermatological conditions and we’re proud to be a platinum sponsor of this Conference, exclusively dedicated to hidradenitis suppurativa (HS).

Over the next few days, our team will join leading scientists, physicians, patient organization representatives and fellow industry colleagues to discuss and debate the most recent cutting-edge data and emergent therapeutic strategies aimed at elevating the standard of care in HS.

HS is a chronic inflammatory and debilitating skin disease with a significant impact on quality of life.1 While important progress has been made in recent years with respect to diagnosis and therapeutic approaches, there remains a need and opportunity to further improve the care of people living with moderate to severe HS.

At EHSF 2024, ��ֳ� is proud to share data from our latest research in HS across seven scientific abstracts including four oral presentations and three posters. In addition, our colleagues will be present at the ��ֳ� exhibition booth to welcome delegates, answer questions, and share information on our HS disease awareness program. Furthermore, delegates attending the conference are invited to attend the ��ֳ� educational Scientific Symposium, ‘Unlocking the Future of HS Care’, on Thursday, Feb 8th (13:45 CET) with the opportunity to hear from eminent opinion leaders.

Conferences such as EHSF 2024 that offer an outstanding scientific program exclusively dedicated to HS support education, scientific exchange and timely collaboration. Together, we can help to advance science and create a brighter future for all.

If you are healthcare professional attending, join the ��ֳ� team for our scientific symposium and visit our booth in the exhibition hall.

We look forward to welcoming you in person at EHSF 2024. See you in Lyon!

about ucb

European Hidradenitis Suppurativa Foundation EHSF dermatology Congress Hidradenitis Suppurativa

432 Likes

��ֳ� at the 1st International Societies for Investigative Dermatology (ISID) Meeting

Vandenbruaene Nathalie — Wed, 10 May 2023 06:40:23 +0000

��ֳ� at the 1st International Societies for Investigative Dermatology (ISID) Meeting

Eimear O'Brien, Global Communications & Company Reputation

Vandenbruaene … Wed 10/05/2023 - 08:40

The Inaugural Meeting of the International Societies for Investigative Dermatology (ISID) is taking place this week in Tokyo, Japan, 10-13^th May 2023. ISID is an organization focused on the advancement of investigative dermatology and cutaneous biology. As a Company committed to advancing patient care in chronic dermatological conditions such as psoriasis and hidradenitis suppurativa (HS), ��ֳ� is proud to participate in this international meeting.

ISID 2023 offers an exciting four-day program of outstanding cutting-edge data and science. We look forward to joining the dermatology community over the next few days to discuss the latest research. Healthcare professionals attending ISID 2023 will have the opportunity to join two ��ֳ� symposia focused on HS and psoriasis:

Understanding Hidradenitis Suppurativa: an educational symposium, Thursday, May 11^th, 12:05 - 13:05 JST
Spotlight on Psoriasis: new perspectives on therapy and pathology, Saturday, May 13^th, 12:05-13:05 JST.

In addition, ��ֳ� is proud and honoured to have two scientific abstracts accepted for presentation at this inaugural meeting, with one focused on hidradenitis suppurativa accepted as an oral presentation, and one on psoriasis accepted as a poster presentation.

At ��ֳ�, we understand that significant unmet needs remain in HS and psoriasis. We are committed to collaboration with the community to help advance science aimed at elevating standards of care. Meetings such as ISID 2023 provide a welcome forum to engage, connect and accelerate progress aligned to our common purpose.

If you are a healthcare professional attending #ISID2023, we look forward to meeting with you in Tokyo.

about ucb

ISIS Hidradenitis Suppurativa HS dermatology International Societies for Investigative Dermatology

410 Likes

Exploring the future of dermatology at AAD 2023

Vanco Vlastimil (��ֳ� S.A.) — Fri, 17 Mar 2023 11:22:35 +0000

Exploring the future of dermatology at AAD 2023

Eimear O'Brien, Global Communications & Company Reputation

Vanco Vlastimi… Fri 17/03/2023 - 12:22

The American Academy of Dermatology (AAD) Annual Meeting takes place this week in New Orleans, Louisiana, U.S., 17-21 March. We spoke with Braulio Gomez, U.S. Medical, ��ֳ� and Owen Davies, Global Medical, ��ֳ� to find out more.

What can you tell us about AAD 2023?
Braulio Gomez: AAD 2023 is among the largest and most significant yearly meetings in the field of dermatology. Each year, this meeting brings together the community for a comprehensive learning experience, offering scientific sessions that comprise symposia, forums and interactive workshops. Hosted in New Orleans this year, it is anticipated that the meeting will attract thousands of medical professionals from all over the world. The event provides an opportunity for distinguished experts, clinicians, and scientists to share their expertise, best practices, and insights in the field of dermatology. As a long-standing participant of AAD, ��ֳ� is committed to advancing research in and to providing solutions that meet the needs of patients across a range of dermatological conditions. We look forward to connecting with the community this week to share and discuss the latest research, collaborate with peers, and explore the future of dermatology.

Can you share more about ��ֳ�’s commitment in the area of dermatology?
Owen Davies: ��ֳ� is committed to improving the lives of individuals affected by immune-mediated inflammatory diseases, and we are passionate about creating a world where these diseases no longer impose a burden on patients. We believe that collaborating closely with the community is crucial to achieving this goal, as it leads to a deeper understanding of patients’ needs, advances in clinical knowledge and scientific understanding. Our Patient Value Strategy places the patient and their experiences at the forefront of everything we do. Through our dermatology partnerships we are able to build strong connections with both the patient and scientific communities. This close collaboration enables us to gain a deep scientific understanding of dermatological conditions and helps us to enhance standards of care and demonstrate our dedication to improving patient outcomes.

Can you tell us about ��ֳ�’s scientific presence at AAD 2023?
Owen Davies: This year, we are excited to share our latest research in moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe hidradenitis suppurativa. We are thrilled to be presenting eight abstracts, which have been accepted as seven posters and one oral platform presentation. These abstracts represent the culmination of our commitment to advancing dermatology research and improving the standard of care for individuals affected by these conditions.

What can healthcare professionals expect to experience at the medical section of ��ֳ�’s booth?
Braulio Gomez: At the medical section of the booth, delegates can look forward to an interactive and immersive experience with the opportunity to learn more about hidradenitis suppurativa, psoriatic arthritis and psoriasis. If you are a healthcare professional attending AAD 2023, we look forward to welcoming you to our booth, where you will have the opportunity to meet members of our ��ֳ� team, discuss the latest research, and explore further innovative approaches to help address patients’ needs.

What are your hopes for the future of dermatology?
Braulio Gomez and Owen Davies: Scientific understanding of many inflammatory dermatological diseases is advancing at an incredible rate – but there’s still much to be done to help people living with these debilitating diseases live to the fullest. At ��ֳ�, we share a vision of a future where innovative science and technology drive progress in disease management. With increased understanding of conditions such as hidradenitis suppurativa, psoriasis, and psoriatic arthritis, we believe that pioneering new approaches to disease management will emerge, providing hope for patients and healthcare providers alike.
Collaboration is also key to growing our collective, scientific understanding of dermatological conditions and we always look for ways to work closely with the most passionate partners as we strive to improve every stage of the patient journey. We look forward to continuing our close collaborations with all stakeholders and we believe that our shared commitment to advancing dermatology research will result in a brighter future for patients and healthcare providers.

Stay up to date with ��ֳ� news from the 2023 AAD Annual Meeting by following us on our social media channels, including Twitter and LinkedIn.

about ucb

AAD 2023 dermatology research Hidradenitis Suppurativa psoriasis psoriatic arthritis

482 Likes

Time to Focus on Hidradenitis Suppurativa

Vanco Vlastimil (��ֳ� S.A.) — Wed, 08 Feb 2023 08:54:23 +0000

Time to Focus on Hidradenitis Suppurativa

Ingrid Pansar, Global Medical Affairs Hidradenitis Suppurativa

Vanco Vlastimi… Wed 08/02/2023 - 09:54

The 12^th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) takes place this week (February 8–10, 2023) in Florence, Italy. We sat down with Ingrid Pansar, Global Medical Lead, ��ֳ� and Marie Hélène Saintmard, EU Medical Strategy Lead, ��ֳ�, to learn more about the conference and about hidradenitis suppurativa (HS).

What can you tell us about the 12^th Conference of the European Hidradenitis Suppurativa Foundation?

Ingrid Pansar: “The 12^th Conference of the European Hidradenitis Suppurativa Foundation is an important event in the HS calendar taking place in Florence, Italy, between February 8 – 10. The conference brings together scientists and physicians from all over the world to discuss the latest research and innovations. The high-quality hybrid scientific program offers attending delegates the opportunity to hear the latest research on this extremely important skin disease. At ��ֳ�, we have a longstanding commitment to developing and delivering science that will make a difference in the lives of people with immuno-dermatological conditions and we are looking forward to joining the community over the next few days.”

Can you tell us more about HS and some of the challenges for people living with this disease?

Ingrid Pansar: “HS is a chronic, recurring, painful and inflammatory skin disease. The main symptoms are nodules, abscesses, and pus-discharging fistulas which typically occur in the armpits, groin and sensitive areas. People with HS experience flare-ups of the disease as well as severe pain, which can have a major impact on quality of life. HS develops in early adulthood, and affects approximately one percent of the population in most studied countries. The symptoms of pain, discharge and scarring are not only a physical burden since people with HS can also experience stigma and reactions from society in response to their symptoms.”

Can you share more about ��ֳ�’s overall presence at EHSF 2023?

Marie Hélène Saintmard: “We’re pleased to be a gold sponsor of EHSF 2023 and to have a strong scientific presence at the conference. Our activities at this year’s conference include an educational satellite symposium, an oral presentation and three poster presentations which will share our latest updates on HS, including a literature review focusing on patient quality of life and other patient-reported outcomes. In addition, we are looking forward to welcoming delegates to our medical booth, as well as our virtual booth, where the team will be pleased to discuss our research, answer questions, and share details of our growing partnership network.”

What can healthcare professionals expect to hear if they attend ��ֳ�’s educational symposium at EHSF 2023?

Marie Hélène Saintmard: “We are pleased to be hosting an educational satellite symposium for healthcare professionals titled, ‘Exploring the patient journey: why time matters.’ on February 8th, from 12:45 – 13:30 CET. At this symposium, international experts will discuss the disease trajectory of HS and offer healthcare professionals invaluable insights on the patient journey. If you are a healthcare professional attending EHSF 2023, we hope you can join us for this educational session.”

Do you have a final message for delegates attending the conference?

Ingrid Pansar & Marie Hélène Saintmard: “EHSF 2023 offers multiple learning experiences, an outstanding scientific program and opportunities to engage with leading experts in HS. We believe that building strong relationships with the dermatology community is the path toward optimizing treatment outcomes, improving the patient experience, and delivering solutions that will make a real difference. We are excited to join the discussions this year and to stay up to date with the latest high-quality research and the most recent innovations. To the healthcare professionals attending EHSF 2023, we look forward to meeting with you and welcoming you to our medical booth and educational satellite symposium. See you soon.”

Find out more about Hidradenitis Suppurativa on ��ֳ�’s dedicated page: Hidradenitis Suppurativa | ��ֳ�.

about ucb

EHSF European Hidradenitis Suppurativa Foundation Hidradenitis Suppurativa dermatology Immunology

539 Likes

Advancing Innovation in Dermatology with Collaborative Partnerships

Chiara Vona — Mon, 21 Nov 2022 13:05:19 +0000

Advancing Innovation in Dermatology with Collaborative Partnerships

Emmanuel Caeymaex, Patient Value Immunology & US Solutions

Chiara Vona Mon 21/11/2022 - 14:05

At ��ֳ�, we are committed to improving the lives of those with immune-mediated inflammatory diseases. We embrace the possibility to create a world free from the burden of chronic inflammatory skin diseases – but we can’t do this alone. Guided by our Patient Value Strategy, our purpose is to join forces with community stakeholders to advance high quality scientific research and debate, address unmet patient needs and enhance critical aspects of the patient pathway. That’s why we maintain deep connections with patient and scientific communities to drive innovation and co-create life-changing solutions.

Since 2015, our Patient Value Strategy has been the driver of ��ֳ�’s approach to delivering value for patients. Our operational model puts patients and their individual experiences at the heart of everything we do – from discovery to development to delivery. ��ֳ� has several strategic dermatology partnerships designed to obtain a better scientific understanding of dermatologic conditions, uncover unmet needs, and improve the standard of care for people living with chronic inflammatory dermatological diseases.

IMPROVING SCIENTIFIC UNDERSTANDING OF INFLAMMATORY SKIN DISEASES

As part of our mission to understand inflammatory skin diseases, ��ֳ� is proud to partner on a new EU Research Project—HIPPOCRATES—to improve diagnostic and therapeutic options for people living with psoriasis (PsO) and psoriatic arthritis (PsA). The overall aim of HIPPOCRATES is to promote the earliest possible diagnosis, increase therapeutic options and improve quality of life for people with PsO and PsA. HIPPOCRATES brings together 26 European partners, with involvement of patients, clinicians, primary care practitioners, regulators, small and medium enterprises, and pharmaceutical companies. The team of experts will evaluate and validate newly discovered biomarker signatures for the early diagnosis of PsA, identification of PsO patients at risk of developing PsA, identification of PsA patients at highest risk of damage progression and for personalized or stratified treatment strategies.

Cross-collaboration is critical to improving scientific understanding of inflammatory dermatological diseases and enhance care. In line with this, ��ֳ�’s partnership with IMI BIOMAP (Biomarkers in Atopic Dermatitis and Psoriasis) aims to identify biomarkers of variation in disease outcomes to address the main unmet needs of people living with atopic dermatitis (AD) and PsO, who often experience high variability in symptoms, disease progression and treatment response. IMI BIOMAP is a partnership that brings together twenty-six academic institutions, five patient organizations and five industry partners to create a pan-EU biospecimen and data resource of high quality, multi-dimensional datasets on skin and blood from more than 50,000 patients. The data resource will be used to examine the causes and mechanisms of these conditions and will be accessible via a central analysis portal. State of the art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling will analyze AD and PsO patient data.

In addition to this, ��ֳ� partners with The Accelerating Medicines Partnership®: Autoimmune and Immune-Mediated Diseases (AMP®-AIM), an initiative from the Foundation for the US National Institutes of Health (FNIH) to dissect unique disease-centric pathways for psoriatic spectrum disease and several other systemic autoimmune disorders. AMP®-AIM will advance scientific understanding of key disease pathways using new tools to map how cell types, cell states, and cell-to-cell interactions network to cause inflammation, abnormal function, and tissue injury. The resulting data will accelerate our understanding of the fundamental mechanisms and causes of autoimmune disease, allow more informed selection of patients for clinical trials and generate new targets for drug development.

��ֳ� is also part of Psorcast, a new non-profit, pre-competitive research study developed by the Digital Biomarker Consortium. Psorcast’s objective is to collect and validate patient generated smartphone-based longitudinal measurements of psoriatic disease digital biomarkers that complement clinical measures and monitor psoriatic disease outside of clinical visits. The Psorcast app allows patients with PsO and PsA to measure and monitor changes in their skin and joints over time. The Digital Biomarker Consortium includes Sage Bionetworks, the Psoriasis and Psoriatic Arthritis Clinics Multi-Center Advancement Network, and several other pharmaceutical companies. Helping to improve PsO and PsA diagnosis, understand their disease pathways and improve monitoring and measurement through these partnerships is just the beginning for us, as we continually strive to create value at every stage of the patient journey.

UNCOVERING UNMET NEEDS

To uncover unmet needs for people living with chronic inflammatory skin diseases, ��ֳ� partners with the International Federation of Psoriatic Disease Associations (IFPA), a pivotal international patient advocacy organization that unites, strengthens, and leads the global psoriatic disease community. Our partnership with IFPA allows us to better understand the unique underserved needs of PsO and PsA patients and support them in addressing the profound impact that psoriatic disease has on their lives, including in work, social activities, relationships and home life.
Furthermore, to help people living with Hidradenitis Suppurativa (HS), ��ֳ� and Stanford University established a multi-year collaboration that, among others, aims to better understand HS sub-populations and at-risk groups. The goal of this is to jointly develop unique solutions that combine clinical, real-world, and other data sets — along with the required expertise — to deliver better patient outcomes. The ��ֳ�-Stanford Digital Health Research Collaborative will enable us to develop a better grasp of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process. By understanding the key unmet needs for people living with dermatological diseases ��ֳ� can, more effectively, create solutions that place these needs at the center.

RAISING THE STANDARD OF CARE

As well as improving scientific understanding of inflammatory diseases and identifying the highest unmet needs, we are committed to improving on delivery and raise the standard of care for people living with dermatological diseases. Given this, ��ֳ� has joined a pre-competitive collaboration with AbbVie, Almirall, GSK, Janssen, Leo Pharma, Lilly, Novartis, Pfizer and Sanofi to improve research into digital solutions for AD. The collaboration effort was led and facilitated by the Digital Medicine Society, a global non-profit organization working to broaden the acceptance of digital medicine to enhance public health. The pre-competitive collaboration arose from the common interest of developing a standardized “Nocturnal Scratch Measurement” to overcome these challenges. Following the year-long collaboration, during which ��ֳ� played a highly active role, the team has created a new suite of resources that will allow clinical researchers and drug developers to understand, communicate and deploy digital measurements of nocturnal scratching in AD patients.

Being liberated from the physical, emotional and social burden attached to inflammatory dermatological diseases is still wishful thinking for many patients, despite immense advances in drug development and the advent of novel therapeutics and targeted treatments. Epicensus is a ��ֳ� initiative that will challenge the status quo. For our Epicensus (Consensus and Action to Elevate Psoriasis Care) program, we have engaged a multidisciplinary council of experts—including clinicians, payors, and patient representatives—to gain a holistic understanding of the complex and multi-faceted diagnostic and treatment journey for patients with psoriasis. The goal is to drive action and initiate a paradigm shift to enhance the delivery of future psoriasis care in Europe optimizing outcomes and finally allow people living with psoriasis to experience life to its fullest.
These projects demonstrate what an exciting time it is in the field of dermatology—with science advancing at an incredible rate—and through connecting stakeholders across the research community and health systems we can realize its full potential.

��ֳ�’s ambition is to launch multiple ground-breaking new therapies in dermatology to make disease prevention and cure a reality. While our goals are exciting and ambitious, they can only be achieved through partnership and collaboration, ground-breaking research and the purpose-driven dedication of our ��ֳ� employees. Together, we can transform the lives of patients and evolve the future of dermatology treatment.

about ucb

psoriasis partnerships dermatology innovation Hippocrates Epicensus IFPA science

488 Likes

��ֳ� is a Proud Sponsor of SPIN 2022!

Vandenbruaene Nathalie — Wed, 06 Jul 2022 07:22:24 +0000

��ֳ� is a Proud Sponsor of SPIN 2022!

Owen Davies, Immuno-Dermatology, ��ֳ�

Vandenbruaene … Wed 06/07/2022 - 09:22

We are pleased to sponsor and participate in the 7th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) which starts today in Paris, France and runs until 8th July. Every three years, the SPIN Congress gathers circa 1,500 delegates from around 90 countries, and this year it will take place in a new hybrid format, enabling participants to join physically and online.

The SPIN congress has a focus on chronic inflammatory skin diseases including psoriasis, atopic dermatitis, vitiligo, alopecia, and hidradenitis suppurativa. At this year’s congress, ��ֳ� has a busy programme of three sponsored symposia focused on psoriasis with the titles and timings summarised below:

Possibilities for Personalized Care in Women Living with Psoriasis: what else can be done? Thursday, 7th July - 12:45–13:45 CEST
Reaching New Heights: Team-driven approaches elevating patient care in psoriasis. Thursday, 7th July – 18:00-19:00 CEST
Reaching new heights: Expecting more from treatment options in psoriasis. Friday, 8th July 2022 - 12:45–13:45 CEST.

In addition to our symposia, we are delighted to have 12 presentations at the congress. The data to be presented include the latest results from clinical studies across our dermatology portfolio that highlight our commitment to addressing unmet needs and elevating standards of care.

SPIN 2022 promises to be an inspiring and stimulating event with the opportunity to hear perspectives on daily medical practice from all over the world. We are proud to be a part of a scientific community that is focused on challenging current thinking and exploring new management strategies in order to improve the lives of those with painful and debilitating skin conditions.

If you are a healthcare professional attending SPIN 2022, do join us at the ��ֳ� exhibition booth. Our team looks forward to welcoming you!

about ucb

Skin Inflammation and Psoriasis International Network SPIN dermatology psoriasis

422 Likes

dermatology

Closing gaps in HS care through community engagement and scientific innovation

Leave a Comment

World Psoriasis Day 2024: Celebrating the invaluable role of family

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

What support or resources do family members need to deepen their awareness and understanding of the conditions?

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

Leave a Comment

��ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

Leave a Comment

Advocating for Change in the Lives of People with Hidradenitis Suppurativa

Leave a Comment

��ֳ� Looks Forward to Joining the HS Community at #EHSF2024

Leave a Comment

��ֳ� at the 1st International Societies for Investigative Dermatology (ISID) Meeting

Leave a Comment

Exploring the future of dermatology at AAD 2023

Leave a Comment

Time to Focus on Hidradenitis Suppurativa

Leave a Comment

Advancing Innovation in Dermatology with Collaborative Partnerships

Leave a Comment

��ֳ� is a Proud Sponsor of SPIN 2022!

Leave a Comment

dermatology

Closing gaps in HS care through community engagement and scientific innovation

Leave a Comment

World Psoriasis Day 2024: Celebrating the invaluable role of family

From a day-to-day perspective, what have been the main challenges of living with psoriasis and psoriatic arthritis?

What practical or emotional support can family members provide to someone living with psoriasis and psoriatic arthritis?

What support or resources do family members need to deepen their awareness and understanding of the conditions?

On World Psoriasis Day 2024, do you have a message to share with families of people living with psoriasis or psoriatic arthritis?

Leave a Comment

������ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

Leave a Comment

Advocating for Change in the Lives of People with Hidradenitis Suppurativa

Leave a Comment

������ֳ� Looks Forward to Joining the HS Community at #EHSF2024

Leave a Comment

������ֳ� at the 1st International Societies for Investigative Dermatology (ISID) Meeting

Leave a Comment

Exploring the future of dermatology at AAD 2023

Leave a Comment

Time to Focus on Hidradenitis Suppurativa

Leave a Comment

Advancing Innovation in Dermatology with Collaborative Partnerships

Leave a Comment

������ֳ� is a Proud Sponsor of SPIN 2022!

Leave a Comment

��ֳ� at EADV 2024: committed to advancing care in immuno-dermatology

��ֳ� Looks Forward to Joining the HS Community at #EHSF2024

��ֳ� at the 1st International Societies for Investigative Dermatology (ISID) Meeting

��ֳ� is a Proud Sponsor of SPIN 2022!